BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 1870701)

  • 1. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
    Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
    Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
    Waters CM; Hunt SP; Jenner P; Marsden CD
    Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
    Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
    Neurosci Lett; 1985 Oct; 61(1-2):195-200. PubMed ID: 3878482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
    Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
    Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study.
    Herkenham M; Little MD; Bankiewicz K; Yang SC; Markey SP; Johannessen JN
    Neuroscience; 1991; 40(1):133-58. PubMed ID: 2052148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in multiple tyrosine hydroxylase mRNAs in the substantia nigra, locus coeruleus and adrenal gland of MPTP-treated parkinsonian monkeys.
    Ohye T; Ichinose H; Ogawa M; Yoshida M; Nagatsu T
    Neurodegeneration; 1995 Mar; 4(1):81-5. PubMed ID: 7600187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
    Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
    Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
    Pifl C; Schingnitz G; Hornykiewicz O
    Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
    Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs.
    Colpaert FC; Degryse AD; Van Craenendonck HV
    Brain Res Bull; 1991 Apr; 26(4):627-31. PubMed ID: 1678307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
    German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
    Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
    Masilamoni GJ; Bogenpohl JW; Alagille D; Delevich K; Tamagnan G; Votaw JR; Wichmann T; Smith Y
    Brain; 2011 Jul; 134(Pt 7):2057-73. PubMed ID: 21705423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.
    Hantraye P; Varastet M; Peschanski M; Riche D; Cesaro P; Willer JC; Maziere M
    Neuroscience; 1993 Mar; 53(1):169-78. PubMed ID: 8469305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman AR; Bioulac B; Brotchie JM; Gross CE
    J Neurosci; 2001 Sep; 21(17):6853-61. PubMed ID: 11517273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.
    Schneider JS; Yuwiler A; Markham CH
    Brain Res; 1987 May; 411(1):144-50. PubMed ID: 2886180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
    Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
    Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
    Miyoshi R; Kito S; Ishida H; Katayama S
    Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.